To characterize the therapeutic response to CDX2-reinstatement and its impact on the broader transcriptome, we performed integrated differential expression analysis using RNA-seq data from all three models (CRC cell lines, xenografts, and PDOs; see STAR Methods). This evidence concerns the gene CDX2 and colorectal carcinoma.